Moderna, Inc. · NASDAQ:MRNA

Moderna — 41st Annual J.P. Morgan Healthcare Conference (January 2023)

32 slides from Moderna's conference presentation, Jan 9, 2023

  1. Slide 1: 41st Annual J.P. Morgan Healthcare Conference

    41st Annual J.P. Morgan Healthcare Conference January 9th, 2023 © 2023 M oderna, Inc. All rights reserved.

  2. Slide 2: Forward-looking statements and disclaimer

    Forward-looking statements and disclaimer This presentation contains forward-looking statements within the meaning of the Priv ate Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential of mRNA as a new class of medicines; anticipated sales under adv ance

  3. Slide 3: Moderna mRNA platform uses the natural flow of information in life to develop medicines

    Moderna mRNA platform uses the natural flow of information in life to develop medicines DNA mRNA Protein Storage Software Applications DNA stores instructions for mRNA is a temporary set of Proteins form the basis of life by proteins in the nucleus instructions for cells to make performing the funct

  4. Slide 4: mRNA is an information molecule that encodes for proteins

    mRNA is an information molecule that encodes for proteins Life uses a quaternary system Computers use a binary system Adenosine (A) Uridine (U) Guanosine (G) Cytidine (C) 4 © 2023 M oderna, Inc. All rights reserved.

  5. Slide 5: Main advantages of mRNA vs small and large molecules

    Main advantages of mRNA vs small and large molecules 1 Large product opportunity 2 Higher probability of technical success 3 Accelerated research and development timelines 4 Greater capital efficiency over time vs. recombinant technology 5 © 2023 M oderna, Inc. All rights reserved.

  6. Slide 6: Moderna's vision for harnessing the power of mRNA

    Moderna’s vision for harnessing the power of mRNA Invest in science to invent novel ways to deliver mRNA into various cell types – each will be a new application, which we call a modality Medicine 2 Medicine 2 Medicine 2 Medicine 2 Medicine 2 Medicine 2 Medicine Medicine22 Medicine 2 Medicine 1 Medi

  7. Slide 7: Inventing a new modality is difficult, time-consuming and expensive

    Inventing a new modality is difficult, time-consuming and expensive Delivery Immunity Translation Because this… …without triggering …to engage with the these… most complex machine in nature and co-opt it to make a protein …has to sneak across this… TLRs RIG-I Moderna is uniquely positioned: focused,

  8. Slide 8: Over the last decade Moderna has created 7 modalities

    Over the last decade Moderna has created 7 modalities, each with development candidates Infectious disease Cancer Intratumoral vaccines Vaccines immuno-oncology Modality 1 Modality 2 Modality 3 Localized regenerative Systemic secreted & cell Systemic intracellular Inhaled pulmonary therapeutics surf

  9. Slide 9: Infectious disease vaccines: significant opportunity to reduce healthcare burden from respiratory viruses

    Infectious disease vaccines: significant opportunity to reduce healthcare burden from respiratory viruses Modality 1: Infectious Disease Vaccines U.S. adults 65+ Within Season Annual Any Respiratory viruses Inpatient Respiratory Virus Outpatient Inpatient Approved Mortality (Attack Rate per 1,000) (

  10. Slide 10: COVID first approved respiratory infectious disease vaccine

    COVID first approved respiratory infectious disease vaccine Modality 1: Infectious Disease Vaccines Respiratory viruses 1 2022 COVID vaccine sales of ~$18.4B 1 COVID-19 vaccine 2 2023 COVID vaccine sales floor of ~$5B from confirmed Advance Purchase Agreements Latent viruses and 2022 contract deferr

  11. Slide 11: RSV Phase 3 trial has reached required number of cases for first interim efficacy analysis

    RSV Phase 3 trial has reached required number of cases for first interim efficacy analysis Modality 1: Infectious Disease Vaccines Respiratory viruses 1 Pivotal Phase 3 RSV efficacy study in older adults (60+) has enrolled 36,604 participants RSV Latent viruses 2 Primary endpoints are safety and vac

  12. Slide 12: Two ongoing Phase 3 flu studies, expecting Southern Hemisphere immunogenicity results in 1Q23

    Two ongoing Phase 3 flu studies, expecting Southern Hemisphere immunogenicity results in 1Q23 Modality 1: Infectious Disease Vaccines Respiratory viruses 1 mRNA-1010 Southern Hemisphere immunogenicity study in adults (18+) is fully enrolled (6,000 participants). Readout expected in 1Q23 Flu 2 mRNA-1

  13. Slide 13: Latent viruses have short-term and long-term health impact

    Latent viruses have short-term and long-term health impact Modality 1: Infectious Disease Vaccines Any Virus Associated disease conditions Approved Vaccine Respiratory viruses Leading infectious cause of birth defects (12-20K congenital CMV cases annually in CMV the U.S. alone)1 Major driver of immu

  14. Slide 14: CMV is a large unmet need in women of childbearing age; Phase 3 CMV trial is ongoing

    CMV is a large unmet need in women of childbearing age; Phase 3 CMV trial is ongoing Modality 1: Infectious Disease Vaccines Respiratory viruses 1 Cytomegalovirus (CMV) is a common infection and is the leading cause of birth defects in the US. About 1 out of every 200 infants in the US are born with

  15. Slide 15: Moderna is currently developing five vaccines against latent viruses

    Moderna is currently developing five vaccines against latent viruses, each representing multi-billion-dollar market opportunities Modality 1: Infectious Disease Vaccines Any Moderna Latent Viruses Approved Respiratory viruses Program Vaccine Cytomegalovirus mRNA-1647 (CMV) Epstein-Barr virus mRNA-11

  16. Slide 16: mRNA personalized cancer vaccine in combination with Keytruda met primary efficacy endpoint in Phase 2b study

    mRNA personalized cancer vaccine in combination with Keytruda met primary efficacy endpoint in Phase 2b study Modality 2: Cancer Vaccines 1 mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% (HR=0.56 [95% CI, 0.31-1.08]; one-sided p value=0.0266) compared with

  17. Slide 17: Phase 1 trial in Chronic Heart Failure has dosed its first patients

    Phase 1 trial in Chronic Heart Failure has dosed its first patients Modality 5: Systemic secreted & cell surface therapeutics 1 In the US, Chronic Heart Failure accounts for ~1 million hospitalizations annually Relaxin (human relaxin-2) is a naturally occurring hormone, Relaxin 2 which is known to c

  18. Slide 18: Encouraging Phase 1/2 data in rare disease indication PA

    Encouraging Phase 1/2 data in rare disease indication PA As of last clinical update (September 8 th, Moderna R&D Day) Modality 6: Systemic intracellular therapeutics Rare Diseases 1 6 patient-years of experience on drug and all participants eligible have decided to continue on Open Label Extension (

  19. Slide 19: First inhaled pulmonary mRNA therapeutic program now in clinic

    First inhaled pulmonary mRNA therapeutic program now in clinic Modality 7: Systemic intracellular therapeutics 1 First collaboration between Moderna and Vertex to address Cystic Fibrosis CF 2 Partner Vertex has initiated Phase 1 trial in Cystic Fibrosis with mRNA encoding for CFTR protein; received

  20. Slide 20: Programs in development

    Moderna as of January 2023 Commercial 4 in Phase 3 9 in Phase 2 48 development Pipeline Moderna COVI D-19 Vaccine/Spikevax®, mRNA-1273.222 and mRNA-1273.214 COVI D boosters, Flu, RSV, CMV PCV, Zika, PA, VEGF-A, next generation programs COVI D boosters Respiratory vaccines Latent vaccines mRNA therap

  21. Slide 21: Moderna's capital allocation priorities

    Moderna’s capital allocation priorities R&D Expense (in $B) ▪ Phase 3 trials: Reinvest in the business and ~4.5 Flu, RSV , CMV & COVID boosters accelerate investment in R&D, ~3.3 ▪ Personalized Cancer Vaccine ~2.0 manufacturing infrastructure ~0.5 ~1.4 investments and company buildout ▪ 48 developme

  22. Slide 22: OriCiro Genomics acquisition improves DNA manufacturing capability

    OriCiro Genomics acquisition improves DNA manufacturing capability 1 Novel development approach for plasmid DNA manufacturing that allows for cell- free, high-fidelity and rapid plasmid manufacturing amplification 2 Industry standard today is E. coli-based DNA production, which comes with technical

  23. Slide 23: Moderna's capital allocation priorities

    Moderna’s capital allocation priorities R&D Expense (in $B) ▪ Phase 3 trials: Reinvest in the business and ~4.5 Flu, RSV , CMV & COVID boosters accelerate investment in R&D, ~3.3 ▪ Personalized Cancer Vaccine ~2.0 manufacturing infrastructure ~0.5 ~1.4 investments and company buildout ▪ 48 developme

  24. Slide 24: We are accelerating the scale up of Moderna

    We are accelerating the scale up of Moderna 2018 2020 2022 0 commercial products 1 commercial product 1 commercial product 21 programs development 25 programs development 48 programs development 9 preclinical 11 preclinical 13 preclinical 11 Phase 1 8 Phase 1 17 Phase 1 1 Phase 2 4 Phase 2 9 Phase 2

  25. Slide 25: Our Original Mission

    Our Original Mission Deliver on the promise of mRNA science to create a new generation of transformative medicines for patients. © 2023 M oderna, Inc. All rights reserved.

  26. Slide 26: Our Mission

    Our Mission Deliver the greatest possible impact to people through mRNA medicines. © 2023 M oderna, Inc. All rights reserved.

  27. Slide 27: Save the Date

    Vaccines Day April 11th R&D Day September 13th Save the Date Events in 2023 ESG Day December 7th © 2023 M oderna, Inc. All rights reserved.

  28. Slide 28: Thank you

    Thank you © 2023 M oderna, Inc. All rights reserved.

  29. Slide 29: Appendix

    Appendix © 2023 M oderna, Inc. All rights reserved.

  30. Slide 30: Intratumoral immuno-oncology: Local delivery of mRNA therapeutic targeting cancer cells

    Intratumoral immuno-oncology: Local delivery of mRNA therapeutic targeting cancer cells Modality 3: Intratumoral immuno-oncology 1 Moderna Triplet program, mRNA-2752, encodes for three proteins, OX40L/IL-23/IL-36γ, which enhance expansion and proliferation of T cells response locally against tumor T

  31. Slide 31: Locally administered mRNA encoding for VEGF-A to promote recovery of cardiac function

    Locally administered mRNA encoding for VEGF-A to promote recovery of cardiac function through partial tissue regeneration Modality 4: Localized regenerative therapeutics 1 Coronary artery disease, the primary cause of ischemic heart failure, affects the arteries providing blood supply to the cardiac

  32. Slide 32: Confidential and Proprietary

    Confidential and Proprietary

Moderna — 41st Annual J.P. Morgan Healthcare Conference (January 2023) on 6ix